1 min read

India remains one of the world's most attractive pharmaceutical markets, but navigating the regulatory pathway can be challenging—especially when determining whether a product requires an Import License or a New Drug Application (NDA).

Understanding the correct approval route is critical for achieving timely market access and avoiding regulatory delays.

When is an Import License Required?

An Import License is generally required when a pharmaceutical product is manufactured outside India and intended for import and commercialization in the country. The application is submitted to the Central Drugs Standard Control Organization (CDSCO) and typically includes product quality, manufacturing, and compliance documentation.

Imported products must demonstrate compliance with applicable Indian regulatory requirements and may require registration of both the product and manufacturing site.

When is an NDA Required?

A New Drug Application (NDA) is required when seeking approval for a new drug that has not yet been approved for marketing in India. This may include:

  • New chemical entities (NCEs)
  • New biological products
  • Certain new indications, dosage forms, or combinations

The NDA pathway involves a more comprehensive review of clinical, non-clinical, and quality data to establish the product's safety, efficacy, and quality.

Key Difference: Product Type Determines the Pathway

The primary distinction lies in the nature of the product:

Import License: Focuses on the authorization to import an already approved product into India.

NDA: Focuses on obtaining approval for a new drug that requires scientific evaluation before commercialization.

Choosing the wrong regulatory pathway can lead to significant delays and additional costs. Early regulatory assessment and dossier due diligence are essential to determine the appropriate CDSCO submission strategy and accelerate market entry into India.

Unsure whether your product requires an Import License or NDA approval in India?

Freyr's regulatory experts can assess your product, identify the optimal submission pathway, and help minimize approval delays.

Contact us today for a personalized India regulatory strategy consultation.